Mold-Tek Packaging Limited (533080) Earnings Call Transcript
July 28, 2025
Earnings Call Speaker Segments
Good day, everyone, and welcome to the earnings conference call for Moltech Packaging Limited, hosted by MK Global Financial Services Limited. Please note that all participant lines are currently in listen-only mode, and once the presentation wraps up, you'll have a chance to ask questions. If you require any help during this call, just press Star followed by zero on your touch-tone phone to signal an operator. At this point, I'll turn the conference over to Nitin Gupta of MK Global Financial Services Limited. Thank you, and the floor is yours, Sir.
Good evening, everyone. I want to welcome management and express our appreciation for the chance to have them with us today. Joining us is J. Lakshman Rao, Chairman and Managing Director. I'll now turn the call over to him so he can give his opening remarks. Over to you, Sir.
Good evening, everyone, and thank you very much. Nitin, I'm delighted to tell you that Moltech Packaging delivered an excellent performance this quarter: revenues jumped 22%, and the EBITDA margin also climbed from 18-odd percent last year to 19.7%. EBITDA per kg rose 29%, while net profit is up roughly 35%. This growth was achievable because every sector is performing very well this year, beginning with the Paint segment, where, thanks to ABG, the numbers have risen considerably, followed by Pharma, which — having crossed breakeven for the first time last year itself — has again grown about 11% over Q4 and begun contributing handsomely to the bottom line, and Food and FMCG, which after a long stretch of several quarters has crossed double digits and nearly hit a 14%–16% growth rate in the current quarter. So, with all the segments doing well, only Lubricant shows negative growth, which was expected in this general monsoon season. Apart from that, all the segments are on a forward run, giving us almost 20%–22% growth in revenue and improved profitability across all sectors. What excites us more at Maltech is the speed at which pharma packaging is being adopted and approved by several major players in the pharma industry.
Like I mentioned during the previous quarter's call, four to six audits have again been conducted, and all of them approved our facilities and began taking our products for trials. So, as you're aware and as I noted at the last quarter meeting, Pharma tends to take a fairly long time, but I'm pleasantly surprised that we managed to break in much faster than others. Moving ahead, several approvals that came through over the last 34 months will begin converting into commercial orders, which should improve the numbers at a better pace over the coming few quarters. And I continue to believe that our set target of 35 crores for Pharma in the current financial year is very much achievable. On the FMCG side as well, as I said last year, printing bottlenecks have been fully eliminated, which let us manage label connectivity and IML product supplies on time. Despite summer being shorter by almost one month — you all know rains began across India right from May, and ice cream and yogurt consumption dropped drastically — even so, we achieved 16% growth in food and FMCG, which I consider a very good indicator of future growth.
Also, our Panipat Thinwahal food products haven't begun yet. Launch is set for August, and that too will contribute to an additional high-value product line of operations for Maltech. So taking all of this together, the future appears good and bright, and we're once again on a high-speed track — over the last couple of years, project implementation and creating greenfield projects have consumed our attention and efforts, and now the time has come for these to be put to better utilization, which will enhance margins and profitability. That is my sincere hope. At this point I'll hand it back to the operator for the question-and-answer session, through which we can go into more detail.
Thanks a lot. We're moving into the Q&A portion now. If you'd like to pose a question, you can hit star and one on your Touchstone phone. Should you want to drop out of the queue, you can press star and do — and we ask participants to use their handsets when asking. Ladies and gentlemen, we'll pause briefly while the queue comes together. Our first question comes from Javeer Shekhavat of Ambit Capital. Please go ahead.
Thanks a lot. And sir, congratulations on a solid quarter. My first question concerns your paints business. Could you put a number on the growth you've recorded, both for the Aditya Birla Grass team and for the remainder of the business? That's my first question, in terms of volumes.
Look, I’d rather not split things out company by company since that would run against our, you know, non-disclosure. But this much I can say: Aditya Birla is the biggest driver behind our growth. That said, even Asian Paints and other companies such as AK and KN were either flat, holding at the prior quarter’s levels, or not growing positively. So from that standpoint, the bulk of the growth came through abc.
Yes, and sir, do you anticipate that this quarterly run rate will hold up through the remainder of the year? And setting aside, say, the quarter-to-quarter fluctuation, which occurred because of seasonal demand — but other than that, do you expect these 5,500 tons of paint containers to more or less carry on for the rest of the year?
So look, our view is that this paint volume will hold at the 5500 to 5400 mark at minimum through the third quarter — actually the second quarter too — since the third quarter tends to soften a bit once Diwali is behind us. That said, the fourth quarter should begin recovering. So all told, we could finish the year somewhere around 21,000 to 22,000 tonnes on the paint side. There's room for it to come in even stronger, depending on how the competitive dynamics among the players unfold.
Sure. So in your press release, you mentioned, let’s say, a few of the newer customers for the pharma business. I see Laurus named there, along with some other pharma companies too. So are those fairly recent approvals? Had you already been talking with them, and then, given that you’ve already guided on the size of the business, does anything change there — let’s say over the next 2 to 3 years — regarding the scale you expect to maintain?
I’m confident that what I guided last quarter will keep happening. Inventia Amen. Laris Lab Pulse — these guys have been, I mean, reviewing us and monitoring our products and testing our products for the last several months. But now they’ve started, at least a couple of them have started giving commercial orders, and a couple of them are yet to release. And I also said some of them — there are several other companies that have been testing our products. So all these numbers will start gradually adding to the pharma business, and I foresee a better number can be achieved even in this current year if things go well. Because a couple of new products that have been approved and commercial orders are issued will be starting in August. So they will contribute maybe a crore of rupees per month in terms of turnover. But a lot of other products that have been approved or are under approval by some of these clients — you start adding, each will be adding, you know, 25 to 40, 50 lakhs per month. So like this, as we accumulate, the numbers can double next year probably — if not, if not at least 50, 60%. So if you reach 35 to 40 this year, probably assuming 50 to 60 crores next year as a certain possibility.
And sir, finally, in your presentation you also said you're working on entering additional non-seasonal industries too. You know, in order to diversify away from products that are seasonal, like ice cream. Could you put numbers on which other segments those would be, and then how big those segments are over the next couple of years? I mean, would it be sizable in the overall scheme of things. Yes, yes.
Take Surfaxil, for instance — that's a detergent product, and right now it's adding a great deal to our Q pack sales. In the same way, Harlich's, which is more of a nutritional drink taken all year round, has begun gaining traction. We also carry a few items from Marico, and those too are entirely annual. Our protein products are likewise consumed annually. Protein intake shows hardly any seasonality. Turning to noodles, that's another item where demand exists in every season. So ice cream and yogurt remain the big ones. Yet at least they are seasonal by nature. Particularly during the rainy season, ice cream and yogurt intake drops substantially in India, and that pattern will persist. Still, thanks to these items — agro products, and micro fertilizers, which again, you know, are needed in the rainy season — they will contribute numbers. Likewise, sweets seed boxes are gaining a lot of traction. We've now launched sippers, which will of course sell more once summer returns. But these sweet boxes perform well in our festival season, which starts now. So from June, July onward, things will begin improving through the end of this year, until new year — there are many festivals and festivities, Christmas included.
So through the end of the year — meaning the calendar year — we'll see demand for those boxes, and right now we're doubling that capacity. Restaurant packs also see demand throughout the year. In this way, reliance on ice creams and yogurt should decline. Compared with five years back, our product mix is different, and today the range we offer is much wider. Production at the Paripat plant begins in August, and it will certainly be ready for the festival demand in the north, and by March, when the next summer arrives, it will be ready for summer too. So that will contribute numbers in food and FMCG. We're therefore confident that the 15%, 16% growth we achieved in food and FMCG can continue.
Yes, sir. The final question concerns your overall outlook for volume, for volume growth. Also regarding capacity, from what I understand you're expanding for ABG too, which is due to be commissioned by the second quarter. And then, of course, this Panipat facility, which comes in starting August onwards. Do you have any other capacities planned?
And in Pharma, capacity is being scaled up step by step too, in line with rising demand. We've even bought a fresh plot of two and a half acres right next to our Sultanpur project. And there, once again, money will go into injection moulding machines, moulds, IBM machines, and a new product range is currently in final consideration as well. Should we move ahead with that range, it could call for some investment too. Not a very large amount, since this isn't greenfield, but there will be reasonable investment in pharma growth. So in that sense, this year as well, investment will be to the tune of 80 to 90 crores. If not 130, 140, which is what we put in over the last three financial years.
Absolutely. What are you anticipating for volume this year in terms of the outlook?
So the volume guidance we're targeting is at least 45,000 tonnes for the full year. It's 43 to 45,000, depending on how the remaining quarters play out. That's the reason we're still maintaining our expectation of 12 to 15% volume growth, or at minimum 18, 20% revenue growth. One encouraging thing is that if you look at per kg sale revenue, it has jumped from 198 last year to 211. And that really contributed well to EBITDA. The reason is that the product mix is improving. We're more pharma-added, and from zero to whatever — nine crores, seven and a half crores now — and food and FMCG have grown considerably. So those two factors are what raised our net revenue per kilogram.
Absolutely. Thanks a lot, sir, and I wish you all the best.
Thanks.
Thanks. Our following question comes from Abhishek Navalgun at Centrum Broking, whose line is now open — please go ahead.
Hi there, thanks for taking the question, and congratulations on the solid results. My first question concerns Asian Paints. During your opening remarks, you noted that a substantial portion of the growth in paints comes from CPG, and you are indicating that the CBG portfolio is mostly flat. However, we were discussing some movement of volumes taking place from, say, non-IML to.
I couldn't quite make out what you said.
Hello. Is that better?
Yes, yes, improved at this point. Yes, yes.
I'm getting at the discussion around, you know, volumes moving from non IML over to IML, where we clearly hold an edge, or perhaps our peers do. So why isn't that showing up in the numbers as such? I'm referring to Asian paints.
Yeah, Asian Paints-related pain is neutral. You recall that during the last two, three years, we actually had negative growth with Asian Paints. There was a 10 to 12% drop across the last three financial years, and this year we're stable. That by itself is a solid sign of, you know, staying fit with Asian Paints through IML. And now IML facilities have been set up at all plants. Previously, we used to supply them from Hyderabad or part of Daman, but now we have a facility at Satara, Vizag and Mysore as well, ready to go with IML, where we've installed robots and compatible moulds. So I'm hoping that should gradually improve our numbers over the next few quarters. So ultimately, I hope we'll end up with a positive digit of growth in Asian Paints too.
Alright. And then regarding capacity utilization, I believe you said Satara would be at 55, 57% in FY27 — sorry, FY25. Yet we were running at roughly 75% utilization at some point, so could you share the figure for the quarter in paints overall, and…
Once more, that isn't particularly impressive, since we've installed a number of additional machines there given their Mahad requirement. As a result, utilization at the Satara plant remains in the 50s — just 50%, 55% — purely because of the surplus capacity built up over the LASIK 6 months, which is gradually being taken up as their Mahad operations at ABG keep improving. And once that really gets going — hopefully during this season, with their season running from July through November — that figure should hopefully rise to 60%, 65%.
Right, right. And I believe we're getting better on the quarterly run rate for pharma, and you mentioned new approvals as well. So I mean, what kind of annual figure are you expecting for this year?
We still believe 35 crores would be a solid figure to hit, up from 7 or 8 crores in the last full year — 8, 9 crores. So that means we'd be quadrupling our numbers. So from 9 crores, or whatever it was last full year, we will definitely be reaching around 35 to 36 crores. And if a few things go according to our plan, it could go even higher.
Right, right, right. And could you share — I mean, within your portfolio, say the effervescent tubes or canisters versus bottles and caps — which part is really gaining more traction, or is it equally the effervescent tubes?
In my view, over half of sales are coming from EV tubes at the moment. Caps and bottles, though, are going to catch up quite soon, since a number of approvals are either pending or have been cleared for trial runs, with FDA approval and client approval applied for. So we have several products — I'd say upwards of 20 products — sitting at various approval stages with clients, and they are being released one at a time. Gravity, for instance, released two, three products in May and June, and now they are discussing the release of another three products. So those numbers will get added in. And with Msnlaris, we have several other clients who have given approval but haven't even begun testing our products. Once approval comes, they move to testing, and after testing comes commercial trials — commercial trial kebab. Sorry, machine trials. Machine trial kebab, then final commercial orders. Even commercial orders won't arrive in millions at first. They start with a couple of lakhs and watch how their lines perform and all of that. Then, at the fourth stage, they go for giving us a major stake. In my view, hardly a couple of clients have adopted us as one of their major suppliers — not even the highest one. We are still getting perhaps 20, 25% of the share from a couple of clients, whereas more than 15 clients have approved us.
So as soon as those 15 clients make us one of their main suppliers, that figure could climb sharply. I don't want to speculate on it at this point, but I'm confident it will look good over the years ahead.
Right? Right. So we're currently working on doubling that capacity. And with this possible expansion, I mean, peak revenue could reach something like 100 crores from pharma.
Right. On our own, existing capacity can get us to 60 to 70 crores, and a fresh brownfield expansion of another 10, 12 crores would push the possible capacity past 100 crores. After that, growth will keep coming steadily, since we've acquired the land I mentioned last quarter — another two and a half acres right next to the present site. That's likely where phase two goes; what's happening this year I'd call phase one, and phase two will be built on that land next year. Definitely the next financial year. The way things are moving, the facility won't be able to contain the growth, so we have to build. These are all pharma buildings, and to hit the interior spec standards, the building alone needs at least nine to 12 months. So we're beginning the blueprint for the new land now as well, though we'll probably only kick off toward the end of this calendar year, with production reached by the middle of next year. Fortunately, for this year's production there's sufficient room in the current building, so we can handle the current year's expansion there, and future expansion will take place on the new land, likely in the next financial year.
Sure. And one final item from my end: the thin wall capacity in the north that we're beginning in August. Do we have any kind of visibility from current customers, say a few FMCG companies, and maybe which categories will be the initial focus? Yeah.
Take Surf Excel at Buddhi, for instance. So the volumes that currently come all the way from Daman or Hyderabad are going to be molded there instead. We've brought on a new client — what's that company — the protein powder we supply from Hyderabad, which will now be converted there — and a range of new sweet boxes for the north market will begin production. A range of ice cream products and yogurt products will get started by February March. So their operations can accordingly reach a level of almost 2,1800 to 2,000 tonnes per annum by next financial year. This year it will ramp up gradually from 0 to 1000 tonnes by end of this financial year and probably 1500 to 1800 tons during the next financial year in the food and FMCG segment.
That's great. Thanks, sir.
Thanks. Our next question comes from Sanchit Narang at Narang family office. The line is yours — please go ahead.
Can everyone hear me clearly?
Yes.
Over to you, Mr. Singchit.
My question is this: we're at 41.8 per kg now. You guided us to 42 rupees per ton for the last quarter. But looking ahead, since Q1 is one of your strongest quarters, how would we get there? 42 rupees, or will we cross it? Do you have the visibility to cross it, or will we fail? Short. I'm a little confused on that.
Once more, this is speculative. I mentioned 42, with 42 rupees being our goal, and we've reached 41.6 already. Moving ahead, naturally, as you noted, this quarter is the strongest. However, stronger quarters could appear if pharma picks up beyond what it did in this Q1. And it can likely protect the bottom line, if not the top line. So I remain confident that for the full year we'll land in the 41 to 42 bracket. And a slight overshoot wouldn't surprise me either.
And in the prior quarter, you provided guidance to us regarding any breakthrough on the JSW to act.
JSW has bought Akonoble. I didn’t claim a breakthrough would happen. What I did say is that the business with Axon Noble will keep going.
Yeah, I was thinking we might get an entry point through actionable. Yeah, yeah. Has there been any discussion about that which hasn't happened yet?
As for that situation, nothing has actually changed—the prior management team is still keeping watch and staying in touch with us. No formal announcement of any change has even been made yet. So at this point I’m not able to say anything. And there’s no certainty on our end that their business will come to us. I said this last time as well: it may happen, or it may not. We’ll only find out once their new management is truly in place.
I appreciate that.
Thanks. We'll take our next question from Shirish Paradeshi at Motila Law school. Go right ahead.
Good evening, Mr. Rao. Thanks for giving me the chance, and congratulations. Could you break down that 11,400 crore by segment for me?
You're referring to 11,400 tons?
Yeah, yeah.
Paint is roughly 5,600. Loops comes in at 2400. Wood and Q pack combined total 3200, with 190 from pharma.
Alright, my second question concerns the chair facility that was mentioned first. So what's the utilization rate at that location, and is it making a meaningful contribution to boosting our EBITDA? Since.
So capacity utilization has picked up somewhat—it's sitting at roughly 68% at this point. And once it gets past 60, 65%, the effect on the bottom line should be decent, maybe not outstanding. We're also in the process of moving Gulf production out of Vizag over to Chayar. The majority of the molds are in place, and we're installing one set of pale manufacturing at CAR to serve the lubricant requirement, since lubricant molds differ from paint molds. So once that kicks off, likely in August, utilization at the charger should rise further.
Okay, another thing I wanted to verify regarding food and FMCG — this kind of growth, I mean, you've offered quite a bit of commentary. But your top two or top three customers, are they signaling that throughput is going to get better and that the product basket will improve as well?
How much throughput improves hinges on how their products perform. Yet the basket gain I foresee is certainly going to materialize, since an increasing number of food and FMCG items are looking for IML containers. Right now we're negotiating with a couple of MNCs on projects that could involve a decent volume of products, which may contribute substantially to the figures. Even where Hul is concerned, this quarter's growth versus the same period a year earlier was quite substantial. I'd rather not state the percentage, but it's certainly a big jump. And moving ahead, we've now brought on board a — which one is that? Marico? We've brought on Nestle and Harle, that is GSK, who have begun packaging their products in IML containers. So once they witness the traction building in the market, there will be considerable interest in the other competing products. Thus we believe that in FMCG there remains a long way to go in terms of growth. Even the shippers we launched for the first time in India with iml are still to take off on a large scale. But we're negotiating with a couple of — if not huge players, then medium-sized ones; generally it's always the mid-sized players who make a quicker decision about changing packaging, and then the biggies follow.
We’re hoping the shippers market will take shape over the next few quarters. That’s another area we’re getting involved in, and we hope it will add to growth in food and fmcc.
Alright, one last question about Panipat — Panipat is now fully operational, and it will be commercialized for most of the products.
Right now, Panipat is running at about 78% this quarter. That's a pretty solid number to hit within a year and a half. And we've already begun Q pack production there. Some of the Q packs for Surf, Excel detergent, and a few of the edible oil suppliers — we've started supplying those from Panipat itself. So going forward, we're adding more machines there this year; the present capacity of 5,000 tons would likely rise to somewhere around 6,500 to 7,000, including food and FMCZ — food and FMCG there is currently maybe 4,500, 600 tons. We'll add another thousand tons now, and perhaps another 7, 800 in the Pale business, which is meant for ABG growth. So Paripat will keep having good traction thanks to the product mix — qpat, food, and pails, almost like its Hyderabad unit. So that's another focus unit for us, and it will probably keep enjoying better capacity utilization.
Alright, just one last follow-up regarding total volume growth. What you delivered this quarter is really strong. But if you need to sustain 15%, which two segments would be the biggest drivers over the remainder of the year? Of course, Paint would be one — Paint.
We'll keep being there on account of abg. The numbers are climbing versus last year, and climbing sharply. So paint will keep contributing solid figures in food and FMCG. And to a larger extent — though it's a small number — pharma in terms of ebitda. Additional are lifting the EBITDA, and pharma will be a major player. As for volumes growth, food and FMCG plus paint will keep on rising.
Alright, thanks very much, and best of luck to you, sir.
I appreciate that.
Thanks. Our following question comes from Pratyush, who is an individual investor. Pratyush, the floor is yours.
Hello there.
Yes, Mr.
Yes, thanks. I’ve got three questions, mostly. First, how long does procurement take—what’s the lead time—for like goods from any customer in each of the segments: paints, FMCG, and pharma?
When you say receiving the goods, what exactly do you mean? I think you mean supplying the goods.
So, take this example: if Asian Paints needs an extra thousand containers in December, they want the distributor to have sold them by December. Then, given how long it takes them to make the paint and then get it supplied, in which months would they likely place that order for the thousand containers with you? Would that be around September or October? Typically, how many months ahead would that be?
Is it a couple of weeks out — two or three weeks ahead of time?
All right. And the same holds true across every sector.
For the most part, hardly anyone holds a large inventory of packaging materials. Typically, they acquire the packaging material only a few days ahead of time, and as soon as it's filled, that's when distribution happens. So, generally speaking.
Alright.
I think the majority of our clients are going to sell through that merchandise in 2 to 3 weeks starting from the moment they buy it from us.
Alright, so on to the second question. For instance, I notice there’s quite a bit in hydrogen, they mention. There’s a company called Time Technoplast that uses polymers to produce containers for hydrogen, CNG, and so on. So I’d like to understand whether that’s something you’ll also do down the road. And if not, is there a really significant difference between plastic packaging and polymer packaging that would keep you from entering that segment?
Right, I do need to look into that. What you're describing with hydrogen packing and the rest — if it involves multi layer film or tubes, that's a different matter from injection molding. With injection molding, you're always dealing with things like containers, and in injection molding in particular, what you get is only white mouth containers. So products that are very gaseous are going to be hard to handle in containers. For that, you need only tubular or multi layer film packing. You can't do it.
Alright, alright.
That's not efficient. Yeah.
All right, final question then. So essentially, some companies have begun producing their own packaging. So what sorts of reasons exist that would keep, say, Asian Paints or any large packaging player from integrating backward and beginning to make their own tubs? Just a question framed around customer confrontation.
Right. No company runs its own packaging manufacturing operations, since producing packaging products simply doesn't make sense. The reason is that the volumes an injection molding machine can turn out are enormous. And when your plant can't consume that output, you're left figuring out how to use up your capacity. So nobody wants the headache of making their own packaging products? Not once in history. It's extremely rare that you'd see it. Perhaps with tins for edible oil. That's because tin is a low-cost product and transport swallows a lot of money. Edible oil companies make most of their tins in house. That's the sole category where packaging products get manufactured. Containers, on the other hand, involve very advanced technology, the investment is massive, and nobody would take the risk of building that as in-house capacity. That's it. Yes, you need not have it.
Alright, just one more question, sir. In pharma generally, or in any sector, to what extent are customers willing to give any single company — for instance Moltech, or any other company in the raw material space — how would you be receiving? Would it be 2050, or how much of their order would be given to you?
Usually, large companies view 20% or 25% as a comfortable share for a single major supplier. But it might surprise you that we have multiple customers where, even now, we supply 100% of what they need. That covers industrial levers, and it even includes Mandalys, which are international. So there are firms such as Shell Mobile and Volvoin where our share as a supplier exceeds 6, 60%. With Castrol, we supply more than 60, 70%. So all of that hinges on the reputation and credentials of the packaging.
Understood, sir.
Thanks so much.
I appreciate that.
Thanks. We'll take the next question from Chirag at Keynote Capitals. Go ahead, please.
Thanks for the chance to ask. Most of what I had has already been covered. That said, I'd like to follow up: you brought up the just-in-time supply chain approach for the fmcg business. Could you tell us what kinds of changes to working capital are happening as a result?
No, no. What "just in time" really means for us is this: in the past, we had trouble with label connectivity — IML label connectivity. The wait used to run almost 3 to 4 weeks, and then delivery to the client added another week on top. So for any new product or new artwork development, we would quote 5 weeks as the supply time. But now, with the added capacity in both printing and die cutting, connectivity can come down to as little as 7 to 10 days. So when we spoke of that improvement in connectivity under just in time, we meant within a week, 10 days. Because, as I said in answer to the earlier question, clients typically plan 2 to 3 weeks of packaging material. They will be planning for supplies on the 1st of the month to arrive by the middle of the month. So where we once needed about a month, or more than a month, to meet a demand like that, today we have cut it to 10 days. That comes thanks to the extra capacity we built in printing, along with better quality and better inventory control. In fact, through this process, inventory will not rise. Instead, inventory becomes a little leaner.
Previously, we would hold inventory for large brands amounting to two to three months. Today, though, that isn't necessary, since we have greater capacity and improved machinery capable of producing smaller batches with few rejections and at a low cost. These upgraded printing facilities therefore let us strengthen our supply connectivity. This matters particularly during peak season, when clients themselves are unable to gauge their demand. They believe they can sell one lakh containers of thousand milliliters in April. Suddenly it becomes two, two and a half lakhs. They then rush to obtain the packaging material, without which they cannot sell. That is precisely when we will be better positioned to respond. Now, with the Enhancer printing facilities.
So that's the meaning, right? If I've got it right, then this means the testing stage where a customer requires multiple changes in their first product batch — we can deliver that faster, and because of that it would be easier for us to obtain approvals from a newer client. One second — the inventory days that we have on our books today are expected to come down with the help of this, correct?
Yeah. For the second one, it's a yes or no. But the first one is definitely a yes, because serviceability gets better in summer, especially during high season — festival packs and that kind of thing. In the past, we would lose a fair number of clients. These days connectivity is faster, and most clients are pleased with our on-time supplies this season. And that's only going to get better, for two reasons. First, Panipat being nearer to the north means we'll now serve northern clients and deliver in 23 days rather than 10 days from Hyderabad. Second, IML quantities can be made quickly on the new machinery we added and moved into production faster than before. So rather than waiting three to five weeks, demand surges can be fulfilled in 10 days. That will make them rely on Maltech more.
That's a fair point, a fair point. So here's my second question. Could you share the breakdown between IML and non-IML for both volume and value?
Right, right. That remains pretty much in line with the prior quarter. It's roughly 75% total IML, with label at 25% non IML. Within non IML, though, there's pharma at whatever 3,4% to be taken out. Pumps too, so skin printing and other decoration will be only around 20%.
Understood, understood.
On a value basis, it remains comparable — 77%, up from 70% in last Q1. So within one year, there's an improvement, with 70% turning into 77%. That means greater uptake of IML and HDL, while non-IML has declined.
So if I've got that right, IML products cost at least 10 percentage more than non-IML ones. Is that accurate?
Using percentages doesn’t really work here, because with large pails—say a 20 liter pail—the pail itself costs 200 rupees. The difference won’t be 20 rupees; it could be 78 rupees. With a small container, though, like a 100 ML container, 4 rupees turns into 450. There it might be 10 to 15%. So it’s higher, but not exactly.
Next question: given that Today has 16,000 in capacity, what capacity should we expect to have by the end of FY26?
Based on the missionary work we've already planned, plus what's expected to come on stream during this financial year, we anticipate that 61,500 could reach roughly 70,000 tons, pharma included. Right now it stands at 6,364. By the close of this financial year, it will likely exceed 70 — 70 to 2000.
All right, that's great. Thanks. Many thanks, sir.
Thanks. We’ll take the next question from Yash Bajaj at Lucky Capital. Your line is open — go ahead.
Yes, good evening, and congratulations on the great set of numbers. So my first question is, what capacity utilization are we at today?
Chair is about 68%, and Panipat stands at 78%. Sorry — JR is 68%.
All right, all right. And in terms of what we're doing, how do we intend to boost capacity, sir — at these 2 plants?
Polyput, as I just mentioned in my answer, will get to nearly 7,000 tons, and that count includes food.
Alright.
Little by little, during August, roughly 1,800 to 1,000 tons of food will come on stream. Q pack capacity already stands at 5,600 tons. A further 800 to 1,000 tons gets added over the coming 4 to 5 months, beginning in August. As a result, by the close of this financial year, an extra 2,000 and 1,000 of food, plus perhaps another 7 to 800 of peel and Q pack, will have come in, taking the total to 7,000 tons by the end of the financial year.
Right, right. But on this one, I think Panhipat stood at 5,000 tons, correct? When it comes to capacity as of today.
Yeah.
All right, all right. And any capacity we're adding isn't meant for paints — it's meant for food and FMCG.
No, partly paint — maybe 500 to 800 will go toward paints, which are also fungible with the Q pack. That covers both in case of ABG sudden but in demand, it can be fungible with qpeg. So that's roughly a thousand tons and about a thousand tons of food.
Got it. My second question, then: this quarter the Loop segment grew 7.8%. Can you help us understand where that growth is coming from? Because for the past 1, 2 years it had been somewhat flattish or declining.
No, no — if you look at the volumes this year as well, it's a degrowth.
Hello there, Mr. Yes.
Sure, so the only decline is versus Q4 — that's a degrowth. Against Q4, it's actually a gain. But versus Q1 of last year, it's down. It has gotten somewhat better. Still, when you look at Q1 of last year — because, you know, this year the rain came very early, right from the start of May. There's rain across the whole south. And that has hit lubricant sales as well.
Alright.
Since freight traffic is going to decline, that's why I believe Loops is seeing negative growth. That said, I suspect it could land back in a 00-type scenario, given that Loops is a fairly stagnant industry when it comes to volume. Sure. And my final question concerns the pharma division.
What sort of run rate should we be exiting at this year? And what targets do we have in place for this year? Because we do have.
We're expecting that 7.4, 7.5 crores. What we hit this year—this quarter—will begin picking up over a couple of quarters. And likely we'll get to a level of 10% plus crores per quarter by the close of this financial year. That ought to land us somewhere near 35, 36 crores across the full year.
Thirty-five, thirty-five, thirty-six.
Understood — that's everything, coming from 10 crores last year.
Sure. That’s everything from my end. Thank you. And best of luck.
Thanks. Our next question comes from Guru Darshan at Kitara Capital. Go right ahead.
Congrats. Apologies if this is a repeat question. I just want to get a handle on what the main drivers behind FMCG growth are — FMCG and FMCG growth in this quarter?
Like I said when I answered earlier questions, growth in food and FMCG came from better serviceability on our side — label connectivity and getting supplies out on time. That's among the main reasons, since clients were always there for us. The problem was our own inability last year to make deliveries on time, and we've fixed that by adding enough capacity in printing and die cutting. At this point label connectivity has gotten better, and supplies have definitely gotten better. And despite a weak summer, we still closed with 16% growth in food — that's plain food. Not counting the Q pack, which is a really satisfying number. Had the summer held up in May, it would have been more than 20%. Even though it didn't, we've hit 16% growth. And one more thing adding to that: some clients are recognizing Moltec's quality and consistency. They're coming back as well. But I'd say what really improved our numbers is our ability to connect the dots.
Okay, understood. On to the second question. When you mention that the farmer segment has reached this even point, do you mean it's breaking even on EBITDA?
No, the bottom line is what we're discussing.
PBT breaking.
Yeah. Pat. Yeah.
Thanks, sir. I really appreciate it.
Much appreciated. Our following question comes from Deepak Saha at NBI Ltd., who is on the line. Kindly proceed.
Hello, this is Audible.
Yes, Deepak. Deepak, sir, go right ahead.
Sir, a couple of questions. First, on the food and HMCG Park. Given that we had these sporadic monsoons, or an inconsistent summer season — so had we had a normal season, you said we could have done 20%. So for the upcoming quarters, that kind of — for the full year, I mean it's not 20%, but for the coming quarters, can 20% kind of a growth be possible? For the food and SMCB side.
The reason is that we're beginning sweet packs manufacturing in Panipat starting August — perhaps the middle of August, the 10th or 15th — we're planning the inauguration of food and FMCG production there already. Q pack production began a few months back, but the sweet boxes will start sometime in the middle of August, and that will gradually pick up over the next quarter. So from Q3 onward I can see the numbers moving toward 20%, if not Q2, and even in Q2 it can be decently good. But Q3 onward I can be sure that we will be able to reach — I mean, we're aiming to reach 20% volume growth in food and FMCC.
Understood. Regarding the split in value between IML and non-IML — did you say 76%? 77% on the value in terms of.
For the IML split, 77 is fine. And 75 for quantity works too.
And unless I'm remembering wrong, the previous remarks indicated that with the move to IML we're fairly confident we'll get to 80% plus. So do you still hold to that sort of expectation for the whole year? Oh, I mean at minimum for the quarters ahead.
Over a full year, within a few quarters, it ought to return to that level, and likely it will settle there. Then again, it may not. You know, there will still be some folks who continue purchasing plain containers and still purchase pharmaceutical, which is mostly unprinted. So in that way, gradually it might level off at roughly 80%, 75. Between 80%.
Understood. And okay, on the raw material side, sir, could you help me understand the mechanism for passing raw material prices down to your customers? Particularly with the volatility in crude oil prices. If you could share some color — do we pass it through immediately? Does it come with a lag, some timeline? If you could share how we operate when passing raw material prices down to consumers?
Right, so it works the way it usually does — sometimes the price from 1 month back applies, or the 3-month average price. On rare occasions, a 6-month average price is used too, for a couple of clients. So mostly, 75% of the clients go with the previous month's pricing.
Understood. Finally, sir, regarding the recycled content piece, I believe earlier we were discussing something like a 20% figure as the minimum usage of that recycled content for some of the industries, and there's also certain margin improvement tied to it. So at present, if you could give us some color, how does that particular number look? Is it good? Because previously we held the belief that this number should rise gradually over time. So if you could share some understanding on that, please.
Yeah. In RCP, utilization is definitely rising, and because some suppliers have proven out the product quality, we're better positioned to consume increasing amounts of RCP. I believe we've already surpassed 7,000 to 7,500 tons of RCP used during this current financial year, which, when you look at that quantity against 38,264 last year, comes close to. Sorry. Against that 11,400 per quarter. Out of 44,000, that's over 15%. And step by step, I think we're moving toward 20% utilization in the current financial year.
Okay, and that matters for industrial. That means paint and nukes, right? I mean, it doesn’t matter for your food and qpex?
Nope, pharma isn't one of them. So that leaves us covering roughly 70% of the volume we handle.
Understood. And regarding.
Yeah.
All right, all right, understood. So just one final point. Regarding how interchangeable these machines are, we probably can. It holds up for pharma and food, while on the other side there’s lubes and paint. So these are fungible, correct? What I mean is, we can’t use paint and pharma capacity to a large extent. I mean, for a small requirement we can. But if you could share some color on the fungibility between segments.
That is a solid question. Paints, loops, and Q pack are all interchangeable. Q pack is also somewhat of a pale, and its margins are likewise comparable to pails. So paint loops and Q pack are interchangeable items, food and pharma. Yes, they are interchangeable, since the mission size, screw size, and even the robotics. Naturally, robotics aren't needed much for pharma apart from tubes under GMP standards. What we do is keep the food allowing certain pharma products to be moulded in the food section; EV tubes, for instance, don't require a DMF facility. So whenever extra capacity is needed in pharma, we can run that in food to some degree. But most pharma products that are purely pharma, we can't run them in food. So there are limitations, yet some scope exists for interchangeability, particularly food products. If demand rises, they can easily be run in pharma, though from a cost perspective it isn't advisable. Even so, to handle a sudden surge in food demand, we can make use of the emissions in the pharmacy.
Understood. That's everything from my side, and best wishes for the remainder of the year. Thanks.
I appreciate that.
Thanks. Our next question comes from Deepak at Sundaram Mutual Fund. Go right ahead.
Thanks for having me. Can you hear me okay?
Yes, Mr. Deepak, go right ahead.
Yes, I just had one question. Earlier, you said the volume mix between IML and non-IML stayed broadly similar, I believe in Q4 of the previous quarter and in Q1. Right. And even though the volume mix between IML and IML is similar, your gross profit per kg has risen by 3 rupees. Right. On a QOQ basis. Now, looking at your volume split, the only difference I could identify is that your paints volume, which contributed around 45% in Q4, has increased to 49%. Right. So your IML stays the same, but your paint volume has risen, and that is what is driving your GP per kg improvement on a QoQ basis. So would it be fair to conclude that the IML mix within the paint segment has gone higher, let's say in Q4 versus Q1 versus Q4? Yes.
Like I mentioned during the previous quarter, Asian paints is increasingly embracing IML across its leading brands, which allowed us to use — it allowed us to install robotic equipment at all five of our plants throughout India at this point. That has, in turn, prompted them to pursue greater IML uptake. This is among the factors behind the improved performance. Still, those figures of 75% and 75% for Q4 and Q1 are somewhat, you know, a bit puzzling, since you ought to note that growth in food and FMCG is what added substantially to the stronger EBITDA margin. And naturally, part of the paints shifting toward IML is also among the reasons.
Right, but looking at the volume mix in your food and FMCG segments, those have actually slipped by a few basis points. So that shouldn’t really drive any meaningful gain in GP per kg. Correct? It must be the IML contribution that’s coming through from paint.
No, no — if you look at the absolute figure, Q4's 1379 tonnes went to 1568 in Q1, which means an increase of nearly 14%.
All right, but when it comes to your volume mix, there’s been no change. That’s the conclusion I’m trying to reach — not at the absolute level, but on the volume mix.
Oh, within the total volume mix it remains 13.79%, which was exactly the case. If that's how you're looking at it, yes. But when it comes to Q4 versus Q1, that increase of 200 tons in food and FMCG contributes reasonably better, since we have almost double the EBITDA compared with paint and loops in food and FMCZ.
So could you tell us, let's say, how IML versus non-IML breaks down across the segments?
Paints, the loops, most likely — those have to be split up and handed over to you by our team. If you send a note to Ramabu, he'll be able to answer.
Alright, thanks for taking the questions, and best of luck to you.
Thanks.
Thanks. Our next question comes from Pranchal Mukhija with Growth Spear Ventures LLP. The line is yours — go ahead.
Sir, can you hear me?
Yes, Mr. Pranjal, go right ahead.
Hello, sir. Thanks for this opportunity, and congratulations on the truly excellent set of numbers. Sir, I have two questions regarding the pharma side. The first one is really just for my own clarity, but it concerns the Sultan facility we’re operating, specifically the pharma portion there. At present, the production capacity at that site stands at 1,500 tons.
Right.
And near term, we expect that to get to 3,000, right?
It won’t be 3,000 — that figure will likely drop to 2,000 fast over the coming six months, and in the next financial year we’ll probably aim for roughly 3,000 to 3,500. So the present plan is to raise capacity to at least 2,000 tons within the next couple of quarters.
Okay, so what type of land is this capacity built on? In terms of acres, say.
At present, the capacity sits in a building footprint of roughly 70, 50,000, plus a 25,000 shed being prepped to serve as a warehouse, which will need a couple of months to finish. I believe that warehouse will also be ready by the end of September. So right now it's housed within 50,000 square feet, and another 25,000 will come on by September. And by that point these new capacities will be added too, so we'll have sufficient space for warehousing and storage. So any — land wise, we acquired two and half acres of land. So within, given the flower index, I think typically we can easily add about 2 to 3 lakh square feet going forward for pharma — not right away, but over the, you know, next few years.
So you're saying it goes from 75,000 to an additional 2 to 3 lakhs.
We could reach 75,000, and on top of that another 2 and a half to 3 lakh square feet is possible on the new land we acquired. Right now it's 50,000, and 25,000 is being added, which will be ready.
With this new land, we can basically 5x pharma capacity — 5x it.
Yes, we could see another 4 to 5x from here.
Right? Thanks, sir — that was insightful. Second, as you mentioned on the call, there are around 20 products under development in pharma. So I just wanted to understand what kind of products these are. Are they somewhat more complex products in terms of how you make them? And how do the realizations on these products compare with the current products we're making — EV tubes, canisters and caps? So I just wanted some clarity on that.
That's a solid question, and I appreciate it, because when I mention 20 products, I don't mean 20 brand-new items — I mean 20 products that the industry actually needs. For instance, as I mentioned before, there's a 300ml jar weighing, say, 25 grams. Certain clients want a thicker bottle, while others prefer a lighter one. So depending on the product, they may want that same 300ml bottle with identical dimensions but at 35 grams rather than 25 grams, or they may want 15 grams. Being able to quickly develop those cores and cavities to adjust the weight is what I'd call a new application. Rather than saying new product, I should have described it as a new application of the same product. We're doing roughly 10 to 15 of those changes, plus another three to four products that are entirely new to our range — though not necessarily new to the industry. In that way, we're broadening our product range and adding value; if these are bottles and caps, as I noted, they sit in the medium range, somewhere around 80 to 100, 120 rupees per kg, maybe 80 to 100. But for other items such as caps and new products, they'll fall in the region of 150, 170 per kilogram.
So now we've also moved into molded wild trail rays, along with the CRC caps. And how do those products stack up against the ones currently being made in.
On the realization terms, those will land in the middle of the order — somewhere around the 120 range. Right.
And so, one final question, if I may. I was hoping for a bit of an update on the export side of the division. As you mentioned, we had supplied some trial quantities in the US, and again, you were looking at, looking for some opportunities in Europe as well. So could you give some update on that, sir?
Yeah, so right now we're actively going after exports to Bangladesh and Europe, since the US is kind of stagnating. Clients have stalled and are waiting for some clarity on the duty structure. So repeat orders haven't come in yet. There's one inquiry in progress, but they're waiting for clarity on the duty structures before they place firm orders. That said, going forward there are opportunities for exports, and we've set up a team to work on that. A two-member team is working on the export push currently. So things will happen. As I said, in pharma it's always a long-run process of approval trials and commercial orders. So that process has started with a couple of clients in the US, one or two clients in Bangladesh, Europe — one client has accepted, then he took a small batch for filling trials. So maybe another few more months down the line something can happen there. And we're also participating in the European Pharma Exhibition sometime in October. Is it October? Pharmaxl End of. End of October. End of October. So probably we'll have better leads and a bigger product range to display when we go there. So I don't count on a big export number this year, but that can start adding reasonable quantities from next year.
Okay, and sir, given that we’re somewhat short on pharma capacity relative to the demand we’re seeing in this segment, how would management distribute the bandwidth when it comes to focusing on pharma divisions in the domestic market versus the export market? And more broadly, what does the realization spread look like — are realizations for pharma products better in export than in India?
Not always. When you factor in freight and the other cost components, Indian and export margins come out roughly the same. Exports are a bit stronger, particularly for items such as canisters and smaller things like caps, yet for bottles and larger products they'll be on par, since shipping consumes a sizable share of the cost. So my take is that exporting to places such as Europe and the US gives slightly better margins, though it's nothing to get too thrilled about.
Okay, thank you sir — those are the questions I have, and I wish the team all the best, sir.
Thanks.
Thanks.
Thanks. That wrapped up the final question for today. At this point, I'll pass the conference back to management for their closing remarks.
I appreciate everyone for joining the Moltech Packaging Q1 conference so actively. I’m also grateful to Nitin from MK for providing us with this opportunity, and thanks to the Operator for running the meeting in such an organized way. Thank you so much, everyone. Have a great day. Bye.
On behalf of MK Global Financial Services limited, thank you. That brings this conference to a close. We appreciate your participation, and at this point you are welcome to disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Mold-Tek Packaging Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Mold-Tek Packaging Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.